These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 17223922)

  • 1. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis.
    Shukla-Dave A; Hricak H; Kattan MW; Pucar D; Kuroiwa K; Chen HN; Spector J; Koutcher JA; Zakian KL; Scardino PT
    BJU Int; 2007 Apr; 99(4):786-93. PubMed ID: 17223922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate volume measured preoperatively predicts for organ-confined disease in men with clinically localized prostate cancer.
    Bianco FJ; Mallah KN; Korets R; Hricak H; Scardino PT; Kattan MW
    Urology; 2007 Feb; 69(2):343-6. PubMed ID: 17320675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Localising prostate cancer: comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy.
    Goris Gbenou MC; Peltier A; Addla SK; Lemort M; Bollens R; Larsimont D; Roumeguère T; Schulman CC; van Velthoven R
    Urol Int; 2012; 88(1):12-7. PubMed ID: 22004874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score to predict positive surgical margins.
    Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
    Urology; 2004 Sep; 64(3):516-21. PubMed ID: 15351582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer.
    Shukla-Dave A; Hricak H; Akin O; Yu C; Zakian KL; Udo K; Scardino PT; Eastham J; Kattan MW
    BJU Int; 2012 May; 109(9):1315-22. PubMed ID: 21933336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
    Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
    BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.
    Coakley FV; Chen I; Qayyum A; Westphalen AC; Carroll PR; Hricak H; Chen MH; Kurhanewicz J
    BJU Int; 2007 Jan; 99(1):41-5. PubMed ID: 17227490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study.
    Kumar R; Nayyar R; Kumar V; Gupta NP; Hemal AK; Jagannathan NR; Dattagupta S; Thulkar S
    Urology; 2008 Oct; 72(4):859-63. PubMed ID: 18329078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer.
    Sciarra A; Panebianco V; Salciccia S; Osimani M; Lisi D; Ciccariello M; Passariello R; Di Silverio F; Gentile V
    Eur Urol; 2008 Sep; 54(3):589-600. PubMed ID: 18226441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
    J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate.
    Fütterer JJ; Scheenen TW; Heijmink SW; Huisman HJ; Hulsbergen-Van de Kaa CA; Witjes JA; Heerschap A; Barentsz JO
    Invest Radiol; 2007 Feb; 42(2):116-22. PubMed ID: 17220729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels.
    Lawrentschuk N; Fleshner N
    BJU Int; 2009 Mar; 103(6):730-3. PubMed ID: 19154475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging.
    Costouros NG; Coakley FV; Westphalen AC; Qayyum A; Yeh BM; Joe BN; Kurhanewicz J
    AJR Am J Roentgenol; 2007 Mar; 188(3):812-6. PubMed ID: 17312072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy.
    Parivar F; Hricak H; Shinohara K; Kurhanewicz J; Vigneron DB; Nelson SJ; Carroll PR
    Urology; 1996 Oct; 48(4):594-9. PubMed ID: 8886066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer.
    Wang L; Hricak H; Kattan MW; Schwartz LH; Eberhardt SC; Chen HN; Scardino PT
    AJR Am J Roentgenol; 2006 Mar; 186(3):743-8. PubMed ID: 16498101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
    Nishimoto K; Nakashima J; Hashiguchi A; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Oya M; Murai M
    Int J Urol; 2008 Jun; 15(6):520-3. PubMed ID: 18422574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer.
    Vilanova JC; Barceló-Vidal C; Comet J; Boada M; Barceló J; Ferrer J; Albanell J
    AJR Am J Roentgenol; 2011 Jun; 196(6):W715-22. PubMed ID: 21606259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer.
    Ohori M; Kattan MW; Koh H; Maru N; Slawin KM; Shariat S; Muramoto M; Reuter VE; Wheeler TM; Scardino PT
    J Urol; 2004 May; 171(5):1844-9; discussion 1849. PubMed ID: 15076291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
    Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.